The control rate of lung cancer can reach 100%!

Previously, Kangfang Biological introduced its PD-1/VEGF bi-antibody AK112 combined with chemotherapy in the first-line treatment of advanced non-small cell lung cancer at the CSCO meeting, which has attracted widespread attention in the industry.
On September 26, Kangfang Biological published the research.
According to the latest phase II clinical data of AK112, the research shows that the control rate of AK112 on non-small cell lung cancer can reach 100%! Lung cancer has become the malignant tumor with the highest fatality rate in China and even in the world.
Generally, the incidence is advanced and difficult to control.
It is generally divided into two types: non-small cell lung cancer (NSCLC) and small cell lung cancer.
However, most lung cancer patients are non-small cell lung cancer.
Small cell lung cancer accounts for 85%-90% of all lung cancers.
It mainly includes bronchioloalveolar carcinoma, adenocarcinoma, squamous cell carcinoma, carcinoid and large cell carcinoma
.

 In recent years, with the rapid development of medical technology, treatments for non-small cell lung cancer have emerged one after another, but they mainly focus on targeted therapy and immunotherapy
.

Among them, the main representative drugs for targeted therapy are Poziotinib from Spectrum Pharmaceuticals, Amivantamab from Janssen Biologics, TAK-788 (mobocertinib) from Takeda, etc.
; immunotherapy The main representative drugs are Cemiplimab (Cemiplimab) from Regeneron, Tielelizumab (BGB-A317) from BeiGene, Sintilimab Injection (Sintilimab Injection) and so on
.

 As a new star in the field of non-small cell lung cancer treatment, can AK112 continue its legend? It is understood that AK112 has the curative properties of both immunotherapeutic drugs and anti-angiogenesis drugs.
It is the second dual-specificity in the world that Kangfang Biologics has entered the clinical development stage after the dual-antibody PD-1/CTLA-4 (AK104).
Antibody drug, designed based on the company's unique TETRABODY technology, can block the binding of PD-1 to PD-L1 and PD-L2, and block the binding of VEGF to the VEGF receptor at the same time
.

 Previously, the combination therapy of PD-1 antibody and VEGF blocker has shown strong efficacy in a variety of tumor types (such as renal cell carcinoma, non-small cell lung cancer and hepatocellular carcinoma)
.

In view of the co-expression of VEGF and PD-1 in the tumor microenvironment, compared with combination therapy, AK112 as a single drug to block these two targets at the same time may block these two pathways more effectively, thereby enhancing anti-tumor Active
.

 It is reported that its multi-center, open phase II clinical study (AK112-201, NCT04736823) included a total of 37 newly-treated NSCLC patients.
After receiving AK112 combined with paclitaxel + carboplatin or pemetrexed + carboplatin, the results showed , The incidence of ≥3 TRAE was 13.
5%; the incidence of drug-related serious adverse events (SAE) was 8.
1%; no new safety signals other than PD-1 inhibitors and anti-VEGF monoclonal antibodies were found
.

 The picture is from medical notes.
Not only that, a total of 26 newly-treated NSCLC patients completed at least one post-baseline tumor assessment, of which 18 were non-squamous cell carcinoma and 8 were squamous cell carcinoma; 12 were negative for PD-L1 expression, and 11 were positive for PD-L1 expression , 3 cases are unknown
.

The ORR assessed by the investigator was 53.
8%, and the DCR was 100%.
The tumors of 12 SD subjects shrank
.

Among the 7 subjects in the high-dose group (20 mg/kg), the ORR was 57.
1%, and the DCR was 100%.
Among them, the tumors of 3 subjects in SD were reduced by 23.
9%, 27.
3%, and 29.
4%, respectively
.

 In the future, it is hoped that AK112 will be able to highlight the encirclement and go on the market as soon as possible, which will bring hope of survival to lung cancer patients
.

End's previous selection of onlookers Nature is heavy: This malignant tumor with the highest lethality rate may usher in the era of precision treatment.
The hot text has created hundreds of billions of revenue in 6 months.
Why is mRNA so "god"? Hot article latest! The "Patient Zero" of the new crown in the United States has a high probability of appearing in the hot article Cell sub-news around September 2019: Create another miracle of life! Scientists use pluripotent stem cells to successfully cultivate artificial sperm, which can produce healthy offspring.
AJCN: To live longer, eat beans often! Long-term consumption of soybean diet can make the brain "more agile".
Medical immunotherapy | Biosimilars | Vaccines | Drug resistance | Drug targets | Healthy life | Pharmaceutical news | Drug inventory | Pharmaceutical technology | Basic research on side effects of drugs / Translational medicine leukemia | Lung Cancer | Gastric Cancer | Colorectal Cancer | Liver Cancer | Breast Cancer | Pancreatic Cancer | Cardiovascular Diseases | Neurodegenerative Diseases | Intestinal Microbial Medical Devices / Biotechnology In Vitro Diagnosis | Medical Devices | Cell Sequencing | Gene Editing | Assisted Reproduction | Artificial Intelligence | Precision Medicine Policy Anti-cancer Drugs | 4+7 Quantity Procurement | Consumables | Record-filing System | Registrant System | Healthy China | New Edition Essential Medicine Catalog | AI Medical Devices | Telemedicine | Same-share non-equity market/capital IPO | Financing | Cooperation | Funds | Hong Kong Stock Exchange | Science and Technology Innovation Board | Growth Enterprise Market |